🚀 Why it matters
Support for patients & clinicians in everyday life (driving, treatment).
And with COSY + NNT + RRR we can:
✔ Define cut-offs & ranges for prevention studies
✔ Improve trial design
📖 Schubert KM et al. Epilepsia 2025. doi: 10.1111/epi.18602
#Epilepsy
⚡ Epilepsy as a dynamic disease
The current definition (≥60% 10-year recurrence risk) is a strong foundation.
But it implies long-term risk, while many key decisions depend on the next months to years.
#Epilepsy#SeizureRisk#Neurology
🔮 Tools to complement
COSY = Chance of Seizure in the Next Year
Prognostic models: SeLECT, CAVE, RISE
👉 Try them at https://t.co/wQV6MAU5uE
They support driving & treatment decisions with individualized, near-term risk estimates.
#EpilepsyResearch#PredictiveMedicine
🧠 Pop quiz: Which disorder eats away brain volume fastest?
A) Alzheimer’s disease
B) Subarachnoid hemorrhage
C) Autoimmune encephalitis
D) Status epilepticus
(Answer below 👇)
⚡️ EEG after stroke isn’t “just a snapshot” — it’s a window into long‑term risk.
Our new paper in Annals of Neurology shows how early EEG findings can help to predict post‑stroke seizures.
Introducing: SeLECT‑EEG - Here’s what we found👇
#Epilepsy#SeLECTEEG#NeuroTwitter
4/
💡 What this means for practice:
✅ Tailored patient counseling
✅ Smarter follow‑up schedules
✅ New avenues for targeted prevention trials in post‑stroke epilepsy
#StrokeCare#EpilepsyResearch
5/
🔮 The future of epilepsy & driving:
• Personalized calculators 👉 https://t.co/5x3wAG3lXz
• Wearables + AI
• Harmonized global policies
• Self-driving tech = new opportunities
📖 Read the study:
https://t.co/pGIGWzSKhZ
#DigitalHealth#NeuroInnovation#EpilepsyTech
1/
🚗 People with epilepsy (PWE) can drive—but not under outdated bans.
Today, eligibility is based on calculated seizure risk.
How is that risk determined? Enter the COSY model.
📄 Driving in People with Seizures and Epilepsy
🔗 https://t.co/pGIGWzSKhZ
#DrivingWithEpilepsy
4/
⚠️ COSY is helpful but not flawless.
• Oversimplifies real-world factors
• Ignores lifestyle & adherence
• Rarely used directly in clinical guidelines
Still, it's a powerful step toward fair, data-based licensing.
#MedicalAI#NeuroPolicy#EpilepsyCare